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Key points (3-5):
1.	People with higher total anticholinergic burden (ACB) from medications had increased risk of mortality and cardiovascular events.

2.	There was a linear dose response relationship, and an additive effect of combination of drugs with ACB. 

3.	Future research should examine the relationship between ACB and adverse outcomes and possibly minimize the ACB load.





Background: Studies have raised concerns that medications with anti-cholinergic property have potential adverse effects on health outcomes.  
Objectives: The objective of this study is to examine the prospective relationships between total anticholinergic burden (ACB) from medications and mortality, and cardiovascular disease (CVD) in a general population.  
Design: Observational study.
Setting: Community cohort.
Subjects: We examined data collected from 21,636 men and women without cancer at the baseline who participated in a baseline survey 1993-1997 in the European Prospective Investigation into Cancer (EPIC)-Norfolk. They were followed until 2009/2011.  
Methods: We performed Cox-proportional hazards models to determine the associations between total ACB and the subsequent risk of all-cause mortality and incident CVD during the follow up.  
Results: There were a total of 4,342 people who died and 7,328 had an incident CVD during the study follow up (total person years= 322,321 years for mortality and 244,119 years for CVD event). Compared to people with no anticholinergic burden (ACB=0), people with total ACB ≥3 from medications had HRs of 1∙83(1∙53,2∙20) and 2∙17(1∙87,2∙52) for mortality and CVD incidence outcomes, respectively, after adjusting for potential confounders. Repeating the analyses after excluding people with prevalent illnesses, and events occurring within the first 2 years of follow up, only slightly attenuated the results.





The potential adverse effect of medications with anti-cholinergic (antimuscarinic) property is of particular interest in ageing populations as older people are commonly exposed to these medications [1]. Previous research however was conducted in long-term care facilities [2,3], or older people with a specific medical conditions [4]. 

Recent studies have classified drugs with different degree of anticholinergic cognitive burden as class 1 (score value 1), 2 (score value 2) and 3 (score value 3) drugs based on their central effect [5]. Using the same scale, Fox et al did not find deterioration of cognition in people with a diagnosis of Alzheimer’s Dementia (n=224) [6], but in a larger sample of general older population (n=12,250) participating in the Medical Research Council Cognitive Function and Ageing Study (MRC-CFAS) they showed increased cumulative risk of cognitive impairment and mortality [7].

There is also evidence to suggest the relationship between anticholinergic medication use and cardiovascular disease risk [8].  However, whether the use of anticholinergic medications in a general population is associated with increased risk of mortality and incidence of CVD has not been examined previously. 





Participants were men and women aged between 40-79 years from general practice age-sex registers at the study baseline during 1993-1997 in the EPIC-Norfolk, UK.  The detailed study protocol of EPIC-Norfolk have been described previously [9]. Briefly, all eligible community dwelling adults from 35 participating general practices were invited to participate.  A total of 25,639 participants (99∙6% White British) attended a baseline health examination during 1993-1997.  They provided written consent to participate in the study and the Norwich Local Research Ethics Committee approved the study.  

Measurements
Details of data collection and measurement methods were described in Appendix 2 (please see Appendix 1 in the supplementary data on the journal website http://www.ageing.oxfordjournals.org/).  Trained nurses measured weight, height, body mass index (BMI) and blood pressure and non-fasting venous blood samples. At the baseline participants completed a detailed health and lifestyle questionnaire which collected information on participant’s educational status, occupational social class, physical activity, smoking status, alcohol consumption, prevalent illness and medications.  Drugs associated with anti-cholinergic burden (Appendix 1, http://www.ageing.oxfordjournals.org/) were identified by searching the database for exact and similar entries for both generic and brand name drugs.  Each medication was assigned to the corresponding anti-cholinergic score and the total anticholinergic burden (ACB) was calculated using the formula:  {[number of class 1 anti-cholinergic drugs] + [the number of class 2 anti-cholinergic drugs x 2] + [the number class 3 anti-cholinergic drugs x 3]}.  Classification of drugs with ACB was class 0 (none), class 1 (mild), 2 and 3 (severe) [5]. 

Case ascertainment
All participants were identified for death at the Office of National Statistics. Participants were also linked to NHS hospital information system and ENCORE (East Norfolk COmmission Record) for admission episodes. Mortality and incident CVD were identified from the death certificates (Office of National Statistics) or hospital discharge code ICD 9, 401 – 448 or ICD 10, I10 - I79 for CVD incidence.  The follow up methods of EPIC-Norfolk had been previously validated using incident stroke cases [10].

The follow up time started at baseline for this study (date of study enrolment) and ended at end of March 2009 for CVD events and end of December 2011 for mortality outcome. 

Statistical analysis
Statistical analyses were performed using STATA version 10.0 (Texas, USA) (please see Appendix 3 in the supplementary data on the journal website http://www.ageing.oxfordjournals.org/ (​http:​/​​/​www.ageing.oxfordjournals.org​/​​) for details). We performed Cox-proportional hazards models to determine the associations between ACB score groups (ACB score 1 group, ACB score 2-3 group and ACB score >3 group) and the subsequent risk of all-cause mortality and incident CVD using the ACB score 0 group as the reference group.  Multivariable adjustments were made to examine how far the associations might be explained by other known lifestyle, socioeconomic and cardiovascular risk factors.  

We then performed stratified analyses to examine the relationships between total ACB and outcomes by age category (<65 yrs and ≥65 yrs), sex (male and female), social class (manual and. non-manual), educational attainment (low and. high), physical activity level (low and high). To examine the impact of higher total ACB score by every 2 points increase, we constructed Cox regression models using models A, B, C and D described above. Effect of ACB class was further examined by creating eight groups of ACB use (none, class 1 drug alone, class 2 drug alone, class 3 drug alone, class 1+2, class 1+3, class 1+2+3, and class 2+3 users).

As a sensitivity analysis, propensity score matching with nearest neighbour matching was used to control for potentially confounding factors.  
Results

Of 25,639 EPIC-Norfolk participants who attended the first health examination, 21,636 (10,135 men and 11,501 women) were eligible to be included in the study, after excluding participants with any missing values and those with prevalent cancer at the baseline.  The mean follow ups were 14∙9 years (total person years = 322,321 years) for all-cause mortality and 11∙3 years (total person years = 244,119 years) for incident CVD.  During the follow up there were a total of 4,342 participants who died and 7,328 had incident CVD.  The flow diagram of participants and missing data table is shown in the Appendix 4 and 5 in the supplementary data on the journal website (http://www.ageing.oxfordjournals.org/).


Table 1 shows the sample characteristics and the crude rates of outcome events according to the ACB score groups. Significant differences were observed with increasing ACB score group for all variables aside from age.  The participants with the higher ACB score groups (2-3 or >3) at study baseline were more likely to be older and to be women. People in the higher ACB score groups were less active, more likely to be on aspirin, or have had a diagnosis of COPD and asthma, myocardial infarction, stroke and diabetes.  There were a substantially higher proportion of people who smoked (defined as current smoker) in the highest ACB group. With large sample size, although the significant overall trends were observed between the ACB score groups, there were few material differences between occupational social class, educational attainment, level of physical activity, total cholesterol level, and BMI. People who used medications with anticholinergic activity compared to non-users (ACB ≥1 groups vs. 0), had a significantly higher level of systolic BP.  Higher rates of events for mortality and cardiovascular disease were observed with higher ACB score group. The overall crude mortality rates were 10∙8%, 23∙4%, 27∙8% and 33∙7% for ACB score 0, 1, 2-3 and >3 groups respectively.  The respective crude overall cardiovascular events were 14∙0%, 33∙3%, 40∙1% and 49∙3% over the entire duration of follow up.

Table 2 presents the Cox-proportional Hazards Ratios and corresponding 95% confidence intervals (95%CI) for the risk of death and incidence of CVD during the respective study follow up periods by ACB score group.  Consistent results were observed with higher ACB score groups being associated with a worse outcome for both mortality and CVD incidence.  For both outcomes, higher levels of adjustments were associated with attenuation in risk but the HRs remained highly significant. Exclusion of people with prevalent conditions, and exclusion of events occurring within the first two years of follow up did not alter the results. 

Appendix 6 shows the adjusted HRs for mortality and incident CVD outcomes in stratified analyses. In all analyses higher ACB score group was associated with a significantly increased risk of both mortality and incident CVD.  The subgroup analyses demonstrated that participants with higher ACB score and age less than 65 years lacked overlap between 95% confidence intervals but there was considerable overlap between the 95% confidence intervals for each strata of gender, social class, education level and physical activity given the same total ACB. The adjusted HRs for mortality and incident CVD outcomes after excluding people with prevalent chronic co-morbidities (asthma, COPD, diabetes, stroke and MI) by ACB score groups is shown in the Appendix 7 (http://www.ageing.oxfordjournals.org/).  In general similar trends in HRs were observed as those without exclusion of prevalent illnesses.

Appendix 8 A shows the adjusted HRs for selected models as in the table 2 for both mortality and incident CVD outcome by every 2 points increase in ACB score. The crude event rates and data are shown in the Appendix 9 (http://www.ageing.oxfordjournals.org/). In fully adjusted model (model C), every 2 point increase in ACB was associated with an increase in 29% relative risk of death and an increase in 40% relative risk of incident CVD during follow-up. Appendix 8 B shows the risk of mortality and incident CVD outcomes with various combinations of ACB classes. This suggested an ACB class effect with combined use of higher class ACB drugs associated with a worse outcome. The crude event rates and data are shown in the Appendix 10 (http://www.ageing.oxfordjournals.org/). 






We found that people with baseline higher total ACB from medications were at increased risk of mortality and cardiovascular events compared to those with no or lower total ACB in a UK general population of middle and older age.  There appeared to be a linear dose response relationship, as well as additive effect of combination of drugs with different anticholinergic burden. While participants with higher anticholinergic burden were older and more likely to have prior cardiovascular co-morbidities, similar results are seen even after adjustment for these variables and other potential confounders as well as repeating the analyses after excluding those with major prevalent illnesses.  

The existing literature on anticholinergic drugs and mortality shows inconsistent results but they have been conducted on high-risk populations such as participants from elderly residential or long term care facilities [2,3], geriatric wards and nursing homes [11], among the elderly hospitalized patients with hip fracture [12,13], and elderly patients with cardiovascular disease [4].  There are only a few studies which have been conducted among the community dwelling older adults [4,7,15].  In general, the results of these studies are inconsistent. Cohorts of hospitalized participants with hip fractures [12, 13] and community dwelling and institutionalized participants [7] showed that a higher anticholinergic activity was associated with increased mortality.  However other studies of long term or residential care facility participants [2,3], older community dwellers [4, 14] and geriatric wards or nursing homes [11] failed to demonstrate this relationship.

A few potential mechanisms may explain why anticholinergic medications may increase mortality and incidence of CVD.  A recent report suggests that anticholinergic medications are pro-arrhythmic and pro-ischaemic [15]. It has been suggested the inhibition of parasympathetic control of the heart may be associated with increased hemodynamic lability, cardiac ischaemia, and cardiac dysrhythmias in response to cardiac ischaemia [16].  In addition, studies have found that certain anticholinergic drugs such as imipramine and clozapine decrease heart rate variability [17] and this may contribute to adverse cardiovascular events.  Another plausible mechanism is via immuno-modulation as the cholinergic system plays an important role in regulating immune response.  Nicotinic receptor activation causes autonomic and vagal systems to inhibit adaptive and innate immune response [18], and it is possible that inhibition of these systems may lead to an inflammatory response and subsequent increased risk of mortality and CVD in people who already possess risk factors.  

Our study has several strengths.  The data were prospectively collected which reduces recall bias. The sample size was large enough to capture a sufficient number of participants with high anticholinergic burden as well as allow us to test the differences in risk between individuals with higher and lower degrees of anticholinergic burden.  Our sample population had wide age spectrum, social and demographic variation and we were able to take into account co-morbidities, other lifestyle factors. 

Our study has limitations. Due to the requirement to attend a health examination, the response rate at the study baseline (1993-1997) was modest at ~ 40% in EPIC-Norfolk introducing a healthy responder effect from the outset.  Nevertheless, baseline characteristics of the study population are similar to other UK population samples except with a slightly lower prevalence of smokers [9].  Moreover, this should not affect the associations observed within the study participants; if anything, truncation of the distribution is likely to reduce power for any associations. In addition, ~2600 participants were excluded due to missing data and this could potentially introduce bias to the regression coefficients.  The current analysis was not part of the pre-registered analysis plan of the EPIC-Norfolk study and this may have implications on generalisability of the findings as the analysis to some extent is contingent on the data. There were only single measurements of covariates such as cholesterol, blood pressure etc.  The blood sample taken was non-fasting sample and therefore less standardized for some of the parameters (e.g. cholesterol level). Nevertheless, random measurement error is likely only to attenuate any associations observed. Ascertainment of drug exposure was based on a baseline self-report.  We do not know whether participants continued to take their medication over the follow up period as we were unable to measure the pattern and the duration of drug usage over time and this could have led to misclassification. Although we were able to calculate total ACB, we were not able to identify particular drugs which are potentially linked to adverse outcomes. The validity of the models of analysis is unknown but the results appear to be robust to different parameterisations of ACB.


A major limitation in assessing the association between medications and health outcomes is the difficulty in evaluating the possible effect of confounding and reverse causality.  Nevertheless, the associations remained after adjustment for known risk factors for cardiovascular disease and mortality and even after excluding individuals with known prevalent illnesses and those with events in the first few years who may have had preclinical conditions.  Though we cannot exclude residual confounding, the limited data from randomized controlled trials of anticholinergics are also consistent with a causal relationship [8,19].
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Table 1: Sample characteristics of 21,636 men and women of the EPIC-Norfolk (1993/1997-2009/2011) according to the total anticholinergic burden (ACB) score
	ACB score 0 group(n=17,317)	ACB score 1 group(n=2,704)	ACB score 2-3 group (n=1,324)	ACB score >3 group (n=291)	P
Age (years)	57.9 (9.1)	62.9 (8.8)	62.2 (9.2)	63.1 (8.9)	0.07
SexMenWomen	8,068 (47)9,249 (53)	1,348 (50)1,356 (50)	593 (45)731 (55)	126 (43)165 (57)	0.003
Social classProfessionalManagerSkilled non-manualSkilled manualSemi-skilledNon-skilled	1,268 (7)6,475 (37)2,806 (16)3,978 (23)2,239 (13)551 (3)	164 (6)927 (34)464 (17)637 (24)403 (15)109 (4)	68 (5)446 (34)234 (18)321 (24)193 (15)62 (5)	19 (7)80 (27)58 (20)78 (27)43 (15)13 (4)	<0.0001*
Smoking Current-smokerEx-smokerNever smoker	2,038 (12)7,153 (41)8,126 (47)	256 (9)1,324 (49)1,124 (42)	155 (12)626 (47)543 (41)	51 (18)122 (42)118 (41)	<0.0001*
Alcohol use (units/week)	7.5 (9.6)	6.8 (9.6)	6.0 (8.3)	5.2 (7.9)	<0.0001
Education levelNo qualification0-LevelA-LevelHigher degree	5,827 (34)1,886 (11)7,202 (42)2,402 (14)	1,152 (43)255 (9)1039 (38)258 (10)	598 (45)111 (8)504 (38)113 (9)	132 (45)25 (9)108 (37)26 (9)	<0.0001*
Physical activity InactiveModerately inactiveModerately activeActive	4,608 (27)5,017 (29)4,187 (24)3,505 (20)	1,037 (38)760 (28)520 (19)387 (14)	552 (42)361 (27)234 (18)177 (13)	142 (49)86 (30)40 (14)23 (8)	<0.0001*
Cholesterol (mmol/L)	6.1 (1.1)	6.3 (1.2)	6.3 (1.2)	6.4 (1.1)	<0.0001
Systolic BP (mmHg)	134 (18)	140 (19)	137 (19)	138 (19)	0.001
BMI (kg/m2)	26.1 (3.7)	27.0 (4.2)	26.9 (4.1)	27.2 (4.4)	<0.0001
COPD	1,425 (8)	346 (13)	184 (14)	40 (14)	<0.0001
Asthma	896 (5)	630 (23)	204 (15)	58 (20)	<0.0001
Previous MI	253 (1)	222 (8)	153 (12)	31 (11)	<0.0001
Previous stroke	131 (1)	78 (3)	52 (4)	13 (4)	<0.0001
Diabetes	286 (2)	102 (4)	59 (4)	17 (6)	<0.0001
Aspirin use	1,234 (7)	479 (18)	268 (20)	65 (22)	<0.0001
New CVD events	4,939 (29)	1,459 (54)	751 (57)	179 (62)	<0.0001
Deaths	2,833 (16)	887 (33)	498 (38)	124 (43)	<0.0001
Values presented are mean (sd) for continuous and number (%) for categorical data. *overall P value. BP=blood pressure, BMI = body mass index, COPD= chronic obstructive pulmonary disease; MI=myocardial infarction, CVD= cardiovascular diseases. Total anticholinergic burden (ACB) calculated as a score which is the sum of the [number of class 1 anticholinergic drugs, the number of class 2 anticholinergic drugs x2 and the number class 3 anticholinergic drugs x3].  Classification of drugs with ACB class 1, 2 and 3 based on criteria of Anticholinergic Cognitive Burden Scale (Boustani MA, et al 2008;4:311–320). 


Table 2: Risk of mortality and incident cardiovascular event according to total anticholinergic burden score (0, 1, 2-3 or >3) during follow up (1993-2011) in EPIC-Norfolk 

Models 	Mortality(Events (n)/Total N=4,342/21,636)
	ACB score 0 group	ACB score 1 group	ACB score 2-3 group	ACB score >3 group	p-value
A	1.00	1.42 (1.32-1.54)	1.90 (1.73-2.10)	2.20 (1.84-2.64)	<0.00001
B	1.00	1.39 (1.29-1.50)	1.85 (1.68-2.04)	2.07 (1.73-2.48)	<0.00001
C	1.00	1.28 (1.18-1.39)	1.65 (1.49-1.82)	1.83 (1.53-2.20)	<0.00001
D*	1.00	1.34 (1.22-1.48)	1.58 (1.38-1.80)	2.08 (1.63-2.66)	<0.00001
E#	1.00	1.25 (1.16-1.36)	1.63 (1.47-1.81)	1.68 (1.38-2.04)	<0.00001
F	1.00	1.27(1.18-1.38)	1.63(1.48-1.81)	1.82(1.51-2.18)	<0.00001
Models 	Cardiovascular disease incidence(Events (n)/Total N=7,328/21,636)
	ACB score 0 group	ACB score 1 group	ACB score 2-3 group	ACB score >3 group	p-value
A	1.00	1.77 (1.66-1.87)	2.18 (2.02-2.36)	2.48 (2.14-2.88)	<0.00001
B	1.00	1.65 (1.57-1.75)	2.09 (1.93-2.26)	2.40 (2.06-2.78)	<0.00001
C	1.00	1.51 (1.42-1.61)	1.86 (1.72-2.02)	2.17 (1.87-2.52)	<0.00001
D*	1.00	1.70 (1.58-1.83)	1.82 (1.64-2.02)	2.26 (1.84-2.77)	<0.00001
E#	1.00	1.50 (1.41-1.60)	1.85 (1.71-2.01)	2.05 (1.75-2.40)	<0.00001
F	1.00	1.48 (1.39-1.57)	1.81(1.68-1.96)	2.10(1.80-2.44)	<0.00001
ACB = Anticholinergic burden score. 
Model A: adjusted for age and sex.  
Model B: Model A plus smoking, alcohol consumption, physical activity level, education level, occupational social class, systolic blood pressure, cholesterol level and body mass index.  
Model C: Model B plus prevalent conditions asthma, COPD, diabetes, stroke and myocardial infarction.  
Model D:  as in Model B excluding people with prevalent asthma, COPD, diabetes, stroke and myocardial infarction.  
Model E: as in Model C excluding all events occurring within first two years of follow up.  
Model F: Model C plus aspirin use. 







Appendix 1: Anticholinergic Cognitive Burden scoring of drugs 










































* Adapted from: Boustani MA, Campbell NL, Munger S et al. Impact of anticholinergics on the aging brain: A review and practical application. Aging Health 2008;4:311–320.
Appendix 2: Methods of data collection

Measurements
Trained nurses examined individuals at clinic visit. Weight was measured with participants wearing light clothing without shoes.  Height was measured up to the nearest 0∙1 cm using a stadiometer with shoes removed.  Body mass index (BMI) was calculated as weight (kilogramme) divided by height in metres squared (m2). Blood pressure (BP) was measured with an Accutorr monitor (Datascope, Huntingdon, UK) after the participant had been seated for 5 min. We used the mean of two BP measurements for analysis. Non-fasting venous blood samples were taken into plain and citrate bottles. We measured serum total cholesterol with the RA 1000 (Bayer Diagnostics, Basingstoke, UK).

At the baseline participants completed a detailed health and lifestyle questionnaire. Participant’s educational status, occupational social class, and physical activity were obtained from the baseline health and lifestyle questionnaire. Educational status was recorded as no qualification, O- level, A-level, degree or higher qualification. Social class was classified according to the Registrar General’s occupation-based classification scheme. A four-level physical activity index was derived from the validated EPIC short physical activity questionnaire designed to assess combined work and leisure activity.  For stratified analyses, social class was re-categorised into manual (III-manual, IV and V) and non manual (III-non-manual, II and I), educational attainment was re-categorised as low educational attainment (no or O level) and high educational attainment (at least A level) and physical activity was re-categorised as high (active and moderately active) and low (inactive and moderately inactive) physical activity categories. 

Smoking status was categorised as current smoker, ex-smoker and those who have never-smoked.  “Current smokers” were defined as those who answered “yes” to the question “Do you smoke cigarettes now?”.  “Never smokers” were defined as those who answered “no” to the question “Have you ever smoked as much as one cigarette a day for as long as a year?”  All others were classed as “former smokers”. Average alcohol consumption (units/week) was derived from a food frequency questionnaire (FFQ) completed at the baseline.  Prevalent illnesses were determined by a positive response to the question “Has a doctor ever told you that you have any of the following?” followed by a list of options including asthma, COPD, cancer, stroke, heart attack, and diabetes.  

Aspirin, steroid tablets or injections and diuretics use was ascertained by a question “Have you taken (aspirin, steroid tablets or injections and diuretics) continuously for three months or more?”.  Other medications were identified by participant’s response to the question “In the last week have you taken any drugs or medicines either prescribed by your doctors or bought from the chemist? If YES, please name them.”  The medication name or brand, dose and frequency of administration were recorded and each medication was coded exactly as written in the baseline survey into a database.  Drugs associated with anti-cholinergic burden (Appendix Table 1) were identified by searching the database for exact and similar entries for both generic and brand name drugs.  Each medication was assigned to the corresponding anti-cholinergic score and the total anticholinergic burden (ACB) was calculated using the formula:  {[number of class 1 anti-cholinergic drugs] + [the number of class 2 anti-cholinergic drugs x 2] + [the number class 3 anti-cholinergic drugs x 3]}.  

The development of the anti-cholinergic burden (ACB) scale used in this study has been previously reported. Classification of drugs with ACB  was class 0 (none), class 1 (mild), 2 and 3 (severe). Examples of drugs with include atenolol, ranitidine, codeine (class 1), amantadine, carbamazepine, pethidine (class 2) and amitriptyline, oxybutynin, olanzapine (class 3).  The score’s predictive validity in cognitive decline has been shown in three large scale studies and a score of 2 or more was associated with increased mortality in an older population.

Case ascertainment
All participants were identified for death at the Office of National Statistics. Participants were also linked to NHS hospital information system so that admission anywhere in the UK was notified to EPIC-Norfolk. They were also linked to ENCORE (East Norfolk COmmission Record) for admission episodes. Mortality and incident CVD were identified from the death certificates (Office of National Statistics) or hospital discharge code ICD 9, 401 – 448 or ICD 10, I10 - I79 for CVD incidence.  The follow up methods of EPIC-Norfolk had been previously validated using incident stroke cases.





Appendix 3: Methods of data analysis
Statistical analyses were carried out using STATA version 10.0 (Texas, USA). We performed Cox-proportional hazards models to determine the associations between total ACB and the subsequent risk of all-cause mortality and incident CVD using the ACB score 0 group as the reference group 

Multivariable adjustments were made to examine how far the associations might be explained by other known lifestyle, socioeconomic and cardiovascular risk factors.  We adjusted for age and sex in model A and age, sex, lifestyle behaviours (smoking status, alcohol consumption and physical activity), social class, education level, systolic blood pressure, serum cholesterol level and BMI in model B. To account for illness driving the higher ACB score as well as contributing as confounder for outcomes examined, prevalent medical conditions including asthma, COPD, diabetes, stroke and myocardial infarction are additionally included in the model C.  Further sensitivity analyses were conducted. Model D was constructed as in model B after excluding people with prevalent asthma, COPD, diabetes, stroke and myocardial infarction (MI).  Model E excluded all events occurring within the first two years of follow up for both outcomes and adjusted as in model C.  Model F was constructed as in model C and additionally adjusted for aspirin use.

We then performed stratified analyses to examine the relationships between total ACB and outcomes by age category (<65 yrs and ≥65 yrs), sex (male vs. female), social class (manual vs. non-manual), educational attainment (low vs. high), physical activity level (low vs. high). In all analyses adjustments were made for age, smoking status, alcohol consumption, systolic blood pressure, cholesterol level, BMI, prevalent conditions including asthma, COPD, diabetes, stroke and myocardial infarction.  In stratified analyses we also adjusted for other factors e.g. in age stratified analysis also adjusted for sex, social class, education level and physical activity level.  The analyses were repeated after excluding those who reported prevalent illnesses at the baseline including asthma, COPD, diabetes, stroke and MI.

To examine the impact of higher total ACB by every 2 points increase, we constructed Cox regression models using models A, B, C and D described above. Effect of ACB class was further examined by creating eight groups of ACB use (none, class 1 drug alone, class 2 drug alone, class 3 drug alone, class 1+2, class 1+3, class 1+2+3, and class 2+3 users). The hazards ratios were calculated using the non-ACB users as the reference group for both mortality and CVD end points using fully adjusted model (Model C).

As a sensitivity analysis, propensity score matching with nearest neighbour matching was used to control for potentially confounding factors. This was used to account for differences in clinical characteristics based on anticholinergic burden score.  A propensity score was estimated for anticholinergic burden score considering the following variables: age, sex, social class, smoking status, alcohol consumption, education level, physical activity, cholesterol, systolic blood pressure, body mass index, asthma, previous myocardial infarction, previous stroke and previous diabetes.   A 1-to-1 matched cohort was generated by using Mahalanobis distance matching with the propensity score as the distance matrix. Three groups were matched: ACB score 1 group vs. ACB score 0 group, ACB score 2-3 group vs. ACB score 0 group, and ACB score >3 group vs. ACB score 0 group. The balance achieved by matching was assessed by descriptive statistics for the variables used to generate the propensity score.  We estimated adjusted odds ratios and Cox proportional hazards for matched groups.

























Appendix 5: Missing data table
Variable	Missing data

















Appendix 6: Subgroup multivariable adjusted analysis of the risk of mortality and cardiovascular events according to total anticholinergic burden score (0, 1, 2-3 or >3) during follow-up (1993-2011) 

	Mortality 	Cardiovascular disease incidence
	ACB score 0 group	ACB score 1 group	ACB score 2-3 group	ACB score >3 group	P-for trend	ACB score 0 group	ACB score 1 group	ACB score 2-3 group	ACB score >3 group	P for trend 
Age<65≥65	1.00(n/N=1,420/15,151)1.00(n/N=2,922/6,504) 	1.51 (1.30-1.75)1.20 (1.10-1.32)	1.58 (1.30-1.92)1.65 (1.47-1.85)	2.93 (2.16-3.99) 1.48 (1.18-1.86)	<0.0001<0.0001	1.00(n/N=3,555/1,5132)1.00(n/N=3,773/6,504)	1.66 (1.51-1.83)1.40 (1.30-1.52)	1.85 (1.63-2.09)1.86 (1.67-2.06)	2.88 (2.32-3.57) 1.68 (1.36-2.08) 	<0.0001<0.0001
SexMenWomen	1.00(n/N=2,521/1,0135)1.00(n/N=1,821/11,501) 	1.32(1.19-1.46)1.21 (1.07-1.37) 	1.56 (1.36-1.79)1.74 (1.50-2.02)	2.05 (1.61-2.62) 1.61 (1.22-2.13)	<0.0001<0.0001	1.00 (n/N=3,960/10,135)1.00 (n/N =3,368/11,501) 	1.56 (1.44-1.70)1.44 (1.31-1.58) 	1.81 (1.61-2.02)1.93 (1.72-2.16) 	2.60 (2.10-3.22) 1.83 (1.48-2.27)	<0.0001<0.0001
Social classNon-manualManual	1.00(n/N=2,520/13,009)1.00(n/N =1,822/8,627) 	1.27 (1.15-1.41)1.30 (1.15-1.47) 	1.67 (1.46-1.91)1.63 (1.41-1.89) 	2.14 (1.68-2.73) 1.55 (1.18-2.04)	<0.0001<0.0001	1.00 (n/N =4,134/13,009)1.00 (n/N =3,194/8,627)	1.52 (1.40-1.65)1.50 (1.37-1.65)	1.90 (1.70-2.11)1.81 (1.61-2.04)	2.23 (1.81-2.76) 2.06 (1.65-2.56)	<0.0001<0.0001
Education levelLowHigh	1.00(n/N =2,359/9,986)1.00(n/N =1,983/11,650)	1.21 (1.09-1.35)1.38 (1.23-1.56) 	1.64 (1.44-1.86) 1.63 (1.39-1.91) 	1.58 (1.23-2.04) 2.15 (1.65-2.81) 	<0.0001<0.0001	1.00 (n/N =3,882/9,986)1.00 (n/N =3,446/11,650) 	1.49 (1.37-1.62)1.55 (1.41-1.70) 	1.88 (1.69-2.09)1.84 (1.63-2.08) 	1.94 (1.57-2.39) 2.49 (2.00-3.10)	<0.0001<0.0001
Physical activity levelLowHigh	1.00(n/N =3,046/12,563)1.00(n/N =1,296/9,073) 	1.33 (1.21-1.45)1.21(1.03-1.41) 	1.69 (1.51-1.89)1.56 (1.27-1.92) 	1.93 (1.58-2.36) 1.56 (1.01-2.41) 	<0.0001<0.0001	1.00 (n/N =4,757/12,563)1.00 (n/N =2,571/9,073)	1.51 (1.40-1.62)1.52(1.36-1.70)	1.89 (1.72-2.08)1.81 (1.55-2.10)	2.10 (1.77-2.49) 2.49 (1.79-3.45) 	<0.0001<0.0001

In all analyses adjustments were made for age, smoking status, alcohol consumption, systolic blood pressure, cholesterol level, body mass index, prevalent conditions including asthma, COPD, diabetes, stroke and myocardial infarction.  Lower occupational social class was defined as skilled manual worker, semi-skilled worker and non-skilled worker.  Upper occupational social class was defined as professionals, managerial or skilled non-manual worker.  Low education level was defined as no qualifications or O level.  High education level was defined as A level or a higher degree.  Low physical activity level was defined as inactive or moderately inactive.  High physical activity level was defined as moderately active or active


Appendix 7: Subgroup multivariable analysis of the risk of mortality and cardiovascular events according to total anticholinergic burden score (0, 1, 2-3 or >3) during follow-up (1993-2011) after excluding prevalent illnesses


	Mortality 	Cardiovascular disease incidence
	ACB score 0 group	ACB score 1 group	ACB score2-3 group	ACB score >3 group	P-for trend	ACB score 0 group	ACB score 1 group	ACB score 2-3 group	ACB score >3 group	P for trend 
Age<65≥65	1.00(n/N=1,037/12,347)1.00(n/N =1,992/4,895)	1.68 (1.40-2.02)1.25 (1.11-1.40)	1.42 (1.09-1.85)1.62 (1.39-1.90)	2.85 (1.86-4.37) 1.82 (1.34-2.45)	<0.0001<0.0001	1.00(n/N=2,611/12,347)1.00(n/N =2,659/4,895)	1.90 (1.69-2.14)1.57 (1.42-1.73)	1.82 (1.55-2.12)1.81 (1.58-2.08)	2.93 (2.19-3.92) 1.80 (1.35-2.40)	<0.0001<0.0001
SexMenWomen	1.00 (n/N =1,699/7,903)1.00(n/N =1,330/9,339)	1.38 (1.21-1.57)1.30 (1.12-1.51)	1.46 (1.20-1.77)1.68(1.40-2.03)	2.41 (1.71-3.39)1.83 (1.28-2.61)	<0.0001<0.0001	1.00 (n/N =2,733/7,903)1.00 (n/N =2,537/9,339)	1.78 (1.60-1.97)1.62 (1.46-1.81)	1.89 (1.62-2.20)1.77 (1.54-2.04)	2.78 (2.05-3.75) 1.92 (1.45-2.54)	<0.0001<0.0001
Social classNon-manualManual	1.00(n/N =1,753/10,369)1.00(n/N =1,276/6,873)	1.37 (1.21-1.56)1.30 (1.11-1.51)	1.53 (1.28-1.83)1.65 (1.36-2.01)	2.47 (1.74-3.51)1.78 (1.26-2.50)	<0.0001<0.0001	1.00(n/N =2,934/10,369)1.00(n/N =2,336/6,873)	1.69 (1.53-1.87)1.70 (1.53-1.91)	1.93 (1.68-2.22)1.69 (1.45-1.98)	2.44 (1.81-3.31)2.11 (1.59-2.78)	<0.0001<0.0001
Education levelLowHigh	1.00(n/N =1,643/7,971)1.00 (n/N =1,386/9,271)	1.23 (1.08-1.41)1.50 (1.30-1.74)	1.55 (1.31-1.84)1.57 (1.27-1.95)	1.85 (1.34-2.56) 2.47 (1.70-3.59)	<0.0001<0.0001	1.00(n/N =2,803/7,971)1.00(n/N =2,467/9,271)	1.62 (1.47-1.79)1.82 (1.63-2.04)	1.83 (1.60-2.10)1.79 (1.53-2.11)	1.97 (1.50-2.59) 2.78 (2.04-3.80)	<0.0001<0.0001
Physical activity levelLowHigh	1.00(n/N =2,070/9,791)1.00(n/N =959/7451)	1.40(1.25-1.57)1.26 (1.04-1.53)	1.63 (1.40-1.90)1.43 (1.08-1.90)	2.28 (1.73-2.99) 1.69 (0.97-2.96)	<0.0001<0.0001	1.00(n/N =3,339/9,791)1.00(n/N =1,931/7,451)	1.66 (1.52-1.82)1.82(1.59-2.07)	1.83 (1.62-2.07)1.79 (1.48-2.16)	2.21 (1.75-2.79) 2.56 (1.66-3.95)	<0.0001<0.0001
In all analyses adjustments were made for age, smoking status, alcohol consumption, systolic blood pressure, cholesterol level, body mass index, prevalent conditions including asthma, COPD, diabetes, stroke and myocardial infarction and prevalent illnesses were excluded.  In the stratified analyses, sex, social class, education level and physical activity were included in the models apart from the variable used for stratification.   Lower occupational social class was defined as skilled manual worker, semi-skilled worker and non-skilled worker.  Upper occupational social class was defined as professionals, managerial or skilled non-manual worker.  Low education level was defined as no qualifications or O level.  High education level was defined as A level or a higher degree.  Low physical activity level was defined as inactive or moderately inactive.  High physical activity level was defined as moderately active or active.







Appendix 9: Hazard ratios (HR) and corresponding 95% confidence intervals (95%CI) for risk of mortality and cardiovascular events during follow up (1993/97-2009/11) in EPIC-Norfolk by every two points increase in anticholinergic burden score according to various models of adjustment

Models of adjustment	Mortality	Cardiovascular disease incidence
	n events/ total N	HR (95% CI)	n events/ total N	HR (95% CI)
Model A	4,342/21,636	1.40 (1.34-1.46)	7,328/21,636	1.51 (1.46-1.56)
Model B	4,342/21,636	1.37 (1.32-1.43)	7,328/21,636	1.47 (1.42-1.52)
Model C	4,342/21,636	1.29(1.24-1.35)	7,328/21,636	1.40 (1.35-1.45)
Model D	3,029/17,242	1.32 (1.25-1.40)	5,270/17,242	1.43 (1.37-1.49)






Appendix 10: Hazard ratios (HR) and corresponding 95% confidence intervals (95%CI) for risk of mortality and cardiovascular events during follow up (1993/97-2009/11) in EPIC-Norfolk by combinations of drugs with contribute to anticholinergic burden score

ACB drug usage	Mortality	Cardiovascular disease incidence
	n events/ total N	HR (95% CI)	n events/ total N	HR (95% CI)
No ACB drugs	2,833/17,317	1	4,939/17,317	1
Class 1	1,262/3,389	1.40 (1.30-1.50)	1,988/3,389	1.66 (1.57-1.76)
Class 2	18/70	1.89 (1.19-3.01)	27/70	1.46 (1.00-2.13)
Class 3	139/619	1.42 (1.20-1.68)	229/619	1.42 (1.24-1.62)
Class 1 & 2 	4/13	1.77 (0.66-4.74)	8/13	1.79 (0.89-3.59)
Class 1 & 3	75/203	1.52 (1.21-1.92)	120/203	1.99 (1.66-2.39)
Class 2 & 3	8/17	2.97 (1.48-5.99)	10/17	2.12 (1.13-3.95)
Class 1& 2 & 3	3/8	1.07 (0.34-3.33)	7/8	6.46 (3.06-13.60)

Adjusted for age, sex, smoking, alcohol consumption, physical activity level, education level, occupational social class, systolic blood pressure, cholesterol level, body mass index, prevalent illnesses including asthma, COPD, diabetes, stroke and myocardial infarction.

Appendix 11: Sample characteristics of propensity matched men and women of the EPIC-Norfolk (1993/1997-2009/2011) according to the total anticholinergic burden (ACB) score
Variable	Matched cohort 1	Matched cohort 2	Matched cohort 3
	ACB score 0 group (n=2,704)	ACB score 1group (n=2,704)	p-value	ACB score 0group (n=1,324)	ACB score 2-3 group(n=1,324)	p-value	ACB score 0 group(n=291)	ACB score >3 group(n=291)	p-value
Age (years)	63 (±9)	63 (±9)	0.05	62 (±9)	52 (±9)	0.89	63 (±9)	63 (±9)	0.93
SexMenWomen	1319 (49%)1385 (51%)	1348 (50%)1356 (50%)	0.43	577 (44%)747 (56%)	593 (45%)731 (55%)	0.53	115 (40%)176 (60%)	126 (43%)165 (57%)	0.36
Social classProfessionalManagerSkilled non-manualSkilled manualSemi-skilledNon-skilled	152 (6%)943 (35%)507 (19%)611 (23%)384 (14%)107 (4%)	164 (6%)927 (34%)464 (17%)637 (24%)403 (15%)109 (4%)	0.55	88 (7%)425 (32%)253 (19%)297 (22%)212 (16%)49 (4%)	68 (5%)446 (34%)234 (18%)321 (24%)193 (15%)62 (5%)	0.60	22 (8%)69 (24%)57 (20%)70 (24%)58 (20%)15 (5%)	19 (7%)80 (27%)58 (20%)78 (27%)43 (15%)13 (4%)	0.29
Smoking Current-smokerEx-smokerNever smoker	280 (10%)1296 (48%)1128 (42%)	256 (9%)1324 (49%)1124 (42%)	0.79	155 (12%)609 (46 %)
560 (42%)	155 (12%)626 (47%)543 (41%)	0.58	40 (14%)139 (48%)112 (38%)	51 (18%)122 (42%)118 (41%)	0.90
Alcohol use (units/week)	6.8 (±9.5)	6.8 (±10)	0.85	5.5 (±7.2)	6.0 (±8.3)	0.08	4.5 (±5.9)	5.2 (±7.9)	0.21
Education levelNo qualification0-LevelA-LevelHigher degree	1147 (42%)276 (10%)997 (37%)284 (11%)	1152 (43%)255 (9%)1039 (38%)258 (10%)	0.85	617 (47%)113 (9%)456 (34%)138 (10%)	598 (45%)111 (8%)502 (38%)113 (9%)	0.76	126 (43%)33 (11%)111 (38%)21 (7%)	132 (45%)25 (9%)108 (37%)26 (9%)	1.00
Physical activity InactiveModerately inactiveModerately activeActive	1068 (40%)785 (29%)490 (18%)361 (13%)	1037 (38%)760 (28%)520 (19%)387 (14%)	0.17	526 (39%)391 (30%)252 (19%)155 (12%)	552 (42%)361 (27%)234 (18%)177 (13%)	0.74	139 (48%)95 (33%)39 (13%)18 (6%)	142 (49%)86 (30%)40 (14%)23 (8%)	0.92
Cholesterol (mmol/L)	6.4 (±1.2)	6.3 (±1.2)	0.30	6.3 (±1.3)	6.3 (±1.2)	0.69	6.5 (±1.2)	6.4 (±1.2)	0.67
Systolic BP (mmHg)	141 (±19)	140 (±19)	0.16	138 (±19)	137 (±19)	0.17	138 (±18)	138 (±19)	0.92
BMI (kg/m2)	27 (±4)	27 (±4)	0.50	27 (±4)	27 (±4)	0.26	28 (±5)	27 (±4)	0.29
COPD	346 (13%)	346 (13%)	1.00	201 (15%)	184 (14%)	0.35	36 (12%)	40 (14%)	0.62
Asthma	595 (22%)	630 (23%)	0.26	189 (14%)	204 (15%)	0.41	49 (17%)	58 (20%)	0.34
Previous MI	210 (8%)	222 (8%)	0.55	157 (12%)	153 (12%)	0.81	37 (9%)	31 (11%)	0.58
Previous stroke	71 (3%)	78 (3%)	0.56	50 (4%)	52 (4%)	0.84	17 (6%)	13 (4%)	0.45
Diabetes	93 (3%)	102 (4%)	0.51	49 (4%)	59 (4%)	0.33	16 (6%)	17 (6%)	0.86
New CVD events	1169 (43%)	1459 (54%)	<0.001	552 (42%)	751 (57%)	<0.001	136 (47%)	179 (62%)	<0.001









 Appendix 12: Propensity matched risk of mortality and incident cardiovascular event according to total anticholinergic burden score (0, 1, 2-3 or >3) during follow up (1993-2011) in EPIC-Norfolk 
Variable	Matched cohort 1	Matched cohort 2	Matched cohort 3
	N	OR or HR	p-value	N	OR or HR	p-value	n	OR or HR	p-value
Logistic regression for death at full follow up	5408	1.45 (1.26-1.65)	<0.001	2648	1.94 (1.59-2.37)	<0.001	582	2.70 (1.77-4.11)	<0.001
Cox proportional hazards for death	5408	1.32 (1.19-1.45)	<0.001	2648	1.65 (1.43-1.89)	<0.001	582	2.01 (1.51-2.69)	<0.001
Logistic regression for CVD at full follow up	5408	1.76 (1.56-1.98)	<0.001	2648	2.32 (1.94-2.80)	<0.001	582	2.25 (1.53-3.31)	<0.001
Cox proportional hazards for CVD	5408	1.45 (1.34-1.57)	<0.001	2648	1.84 (1.64-2.06)	<0.001	582	1.78 (1.42-2.23)	<0.001
Propensity matched for age, sex, smoking, alcohol consumption, physical activity level, education level, occupational social class, systolic blood pressure, cholesterol level, body mass index, prevalent illnesses including asthma, COPD, diabetes, stroke and myocardial infarction


30,445 participated and complete baseline questionnaire during 1993-1997.

21,636 participants included in the analysis.

4,806 participants excluded from analysis because they did not attend the first health check

25,639 participants attended first health check.

4,003 participants excluded from analysis because of prevalent Cancer and missing data (see table below).
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